Total Revenue
Biogen Total Revenue increased by 8.7% to $2.48B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.9%, from $2.43B to $2.48B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows relatively stable performance with a -2.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market demand or successful price increases, while a decrease suggests market saturation or competitive pressure.
Detailed definition
The total amount of income generated by the sale of goods or services related to the company's primary operations. For a...
Peer comparison
Peer technology firms typically report this as Net Sales or Total Revenue, reflecting the scale of their market reach.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.78B | $2.78B | $2.73B | $2.53B | $2.59B | $2.51B | $2.54B | $2.46B | $2.46B | $2.53B | $2.39B | $2.29B | $2.46B | $2.47B | $2.45B | $2.43B | $2.65B | $2.53B | $2.28B | $2.48B |
| QoQ Change | — | +0.1% | -1.6% | -7.4% | +2.3% | -3.1% | +1.4% | -3.2% | -0.3% | +3.0% | -5.7% | -4.0% | +7.6% | +0.0% | -0.5% | -1.0% | +8.8% | -4.2% | -10.1% | +8.7% |
| YoY Change | — | — | — | — | -6.7% | -9.7% | -6.9% | -2.7% | -5.1% | +0.9% | -6.2% | -7.0% | +0.4% | -2.5% | +2.9% | +6.1% | +7.3% | +2.8% | -7.1% | +1.9% |
Product Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| TYSABRI | $462.20M | $406.10M | $415.40M | $381.50M | $454.60M | $431.80M | $397.50M | $441.50M |
| SPINRAZA | $429.10M | $381.40M | $421.40M | $423.90M | $392.70M | $374.00M | $356.20M | $374.00M |
| VUMERITY | $165.80M | $158.10M | $176.60M | $138.80M | $212.30M | $214.60M | $181.10M | $179.00M |
| AVONEX | $182.80M | $176.20M | $170.00M | $166.80M | $177.70M | $188.50M | $162.50M | $163.20M |
| SKYCLARYS | $100.00M | $102.30M | $102.20M | $123.90M | $130.30M | $132.90M | $133.40M | $150.70M |
| BENEPALI | $117.30M | $118.10M | $125.00M | $111.30M | $112.10M | $121.90M | $107.90M | $122.10M |
| TECFIDERA | $252.20M | $232.80M | $227.80M | $206.10M | $193.60M | $168.20M | $111.80M | $109.50M |
| PLEGRIDY | $68.10M | $61.30M | $66.00M | $59.50M | $69.00M | $58.40M | $63.20M | $64.30M |
| ZURZUVAE | $14.90M | $22.00M | $22.90M | $27.70M | $46.40M | $55.30M | $65.70M | $55.40M |
| IMRALDI | $53.20M | $54.10M | $51.00M | $47.40M | $46.70M | $52.60M | $43.50M | $49.60M |
| QALSODY | $5.00M | $11.10M | $11.70M | $15.50M | $20.00M | $26.40M | $25.00M | $32.50M |
| FLIXABI | $13.10M | $16.20M | $16.10M | $13.10M | $14.30M | $15.30M | $9.90M | $10.50M |
| BYOOVIZ | $13.70M | $8.00M | $9.30M | $8.90M | $8.60M | $7.00M | $7.90M | $0.00 |
| FAMPYRA | $18.70M | $19.40M | $14.40M | $300.00K | $0.00 | $0.00 | $1.10M | $0.00 |
| FUMADERM And ADUHELM | $2.70M | $2.10M | $2.70M | $1.70M | $400.00K | $0.00 | $0.00 | $0.00 |
| TOFIDENCE | $800.00K | $200.00K | $100.00K | $100.00K | $0.00 | $0.00 | $600.00K | $0.00 |
| Total | $2.46B | $2.47B | $2.45B | $2.43B | $2.65B | $2.53B | $2.28B | $2.48B |
Spinal Muscular Atrophy was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $2.46B | $2.47B | $2.45B | $2.43B | $2.65B | $2.53B | $2.28B | $2.48B |
| Total | $2.46B | $2.47B | $2.45B | $2.43B | $2.65B | $2.53B | $2.28B | $2.48B |
Total Revenue at Other Companies
Frequently Asked Questions
- What is Biogen's total revenue?
- Biogen (BIIB) reported total revenue of $2.48B in Q1 2026.
- How has Biogen's total revenue changed year-over-year?
- Biogen's total revenue increased by 1.9% year-over-year, from $2.43B to $2.48B.
- What is the long-term trend for Biogen's total revenue?
- Over 4 years (2021 to 2025), Biogen's total revenue has grown at a -2.6% compound annual growth rate (CAGR), from $10.98B to $9.89B.
- What does total revenue mean?
- The total amount of money a company brings in from selling its products and services.